Riskpilot← Back to searchSign inGet full accessMYCOTECH PHARMA AS
ASActiveOrg 985133174Lilleakerveien 2B, 0283 OsloResearch and experimental development on social sciences and humanities · NACE 7220Est. 20020 employeeswww.consorcio.no
Revenue 2021
NOK 0
EBITDA margin
—
+86% vs 2020
Equity ratio
-5310.8%
Financial strength
Net profit 2021
NOK -458K
-86% vs 2020
| Revenue | NOK 0 | — |
| EBITDA | NOK -43K | +86% |
| Net profit | NOK -458K | -86% |
| Total assets | NOK 15K | -97% |
| Equity | NOK -772K | -146% |
| Employees | 0 | — |
Legal name
MYCOTECH PHARMA AS
Org number
985133174
Legal form
Aksjeselskap
NACE code
7220 · Research and experimental development on social sciences and humanities
Founded
26. november 2002
Share capital
NOK 25 000 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2021-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Utvikle, forske, drifte & distribuere produkter og konsepter innen kropp, helse og velvære. Selskapet vil drive konsulentvirksomhet, samt ha mulighet til å investere i andre selskaper.
Address
Lilleakerveien 2B, 0283 Oslo
Website
www.consorcio.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 163 | 460 | 1 068 | 1 155 | 862 | 504 | 338 | 164 | 269 | 278 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −1 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 0 | 24 | 9 | 63 | 213 | −254 | 19 | −76 | 181 | 25 | −641 | −316 | −43 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | 24 | 9 | 63 | 213 | −254 | 19 | −76 | 181 | 25 | −641 | −316 | −43 |
| Net financials | 0 | 0 | 0 | −9 | 0 | −1 | −1 | 0 | −0 | −0 | −1 | −0 | −3 |
| Profit before tax | 0 | 24 | 9 | 54 | 213 | −254 | 18 | −76 | 181 | 25 | −642 | −317 | −46 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −217 | 15 | −141 | −70 | 413 |
| Net profit | 0 | 24 | 9 | 54 | 213 | −254 | 18 | −76 | 398 | 10 | −500 | −247 | −458 |
| Item | 2008 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 22 | 34 | 87 | 272 | 323 | 99 | 131 | 68 | 449 | 611 | 654 | 470 | 15 |
| Equity | −1 282 | −1 094 | 33 | 88 | 301 | 47 | 65 | −11 | 423 | 433 | −67 | −314 | −772 |
| Long-term debt | 0 | 0 | 0 | 31 | 32 | 32 | 37 | 37 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | −18 | 10 | 54 | 154 | −9 | 20 | 29 | 42 | 25 | 178 | 721 | 784 | 787 |
| Total debt | 1 305 | 1 129 | 54 | 185 | 23 | 52 | 66 | 79 | 25 | 178 | 721 | 784 | 787 |
EBITDA margin
-4286600.0%
This company
15.8%
Market median
-27130480% vs market
20082021
Equity ratio
-5310.8%
This company
38.2%
Market median
-14003% vs market
20082021
Return on equity
-45825500.0%
This company
18.4%
Market median
-249051730% vs market
20082021
Net profit margin
-45825500.0%
This company
8.1%
Market median
-565747014% vs market
20082021
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20082021
Debt / equity
1.02×
This company
0.62×
Market median
-65% vs market
20082021
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LV Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KØ | Chairman | 2020 | — | — |
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MYCOTECH PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ludovico-Enrico Vitali-Rosati | Chief Executive Officer | 0 companies |
| Kim Øien | Chairman | 0 companies |
| Frode Marc Bohan | Board of Directors | 0 companies |